The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships

Snowden, Julie S.; Thompson, Jennifer C.; Stopford, Cheryl L.; Richardson, Anna M. T.; Gerhard, Alex; Neary, David; Mann, David M. A.
September 2011
Brain: A Journal of Neurology;Sep2011, Vol. 134 Issue 9, p2478
Academic Journal
Accuracy of clinical diagnosis of dementia is increasingly important for therapeutic and scientific investigations. In this study, we examine diagnostic accuracy in a consecutive series of 228 patients referred to a specialist early-onset dementia clinic, whose brains were subsequently examined at post-mortem. Diagnosis was based on structured history, neurological examination and neuropsychological assessment, with emphasis on qualitative as well as quantitative aspects of performance. Neuroimaging provided support for but did not alter the clinical diagnosis. We set out the principles that guided diagnosis: (i) time course of illness; (ii) weighting of physical, behavioural and cognitive symptoms and signs; (iii) ‘anterior’ versus ‘posterior’ hemisphere character of cognitive change; and (iv) specificity of deficit, paying attention to the differentiation between syndromes of frontotemporal lobar degeneration and focal forms of Alzheimer’s disease. Forty-two per cent of the patients had clinical diagnoses of one of the syndromes of frontotemporal lobar degeneration, the high proportion reflecting the research interests of the group. Forty-six per cent were diagnosed with Alzheimer’s disease and the remaining patients, dementia with Lewy bodies, Creutzfeldt–Jakob disease, vascular or unclassified dementia. Frontotemporal lobar degeneration was identified with 100% sensitivity and 97% specificity and Alzheimer’s disease with 97% sensitivity and 100% specificity. Patients with other pathologies were accurately identified on clinical grounds. Examination of subsyndromes of frontotemporal lobar degeneration showed a relatively predictable relationship between clinical diagnosis and pathological subtype. Whereas the behavioural disorder of frontotemporal dementia was associated with tau, transactive response DNA binding protein 43 and fused-in-sarcoma pathology, cases of frontotemporal dementia with motoneuron disease, semantic dementia and, with one exception, progressive non-fluent aphasia were associated with transactive response DNA binding protein 43 pathology, distinguished by ubiquitin subtyping (types B, C and A, respectively). Clinical diagnoses of progressive apraxia, corticobasal degeneration and progressive supranuclear palsy were, with one exception, associated with Pick, corticobasal and progressive supranuclear palsy subtypes of tau pathology, respectively. Unanticipated findings included Alzheimer pathology in two patients presenting with the behavioural syndrome of frontotemporal dementia and corticobasal pathology in four others with clinical frontotemporal dementia. Notwithstanding such anomalies, which serve as a reminder that there is not an absolute concordance between clinical phenotype and underlying pathology, the findings show that dementias can be distinguished in life with a high level of accuracy. Moreover, careful clinical phenotyping allows prediction of histopathological subtype of frontotemporal lobar degeneration. The principles guiding diagnosis provide the foundation for future prospective studies.


Related Articles

  • A case of atypical progressive supranuclear palsy. Spaccavento, Simona; Del Prete, Marina; Craca, Angela; Loverre, Anna // Clinical Interventions in Aging;2014, Vol. 9, p31 

    Background: Progressive supranuclear palsy (PSP) is a neurodegenerative extrapyramidal syndrome. Studies have demonstrated that PSP can present clinically as an atypical dementing syndrome dominated by a progressive apraxia of speech (AOS) and aphasia. Aim: We aimed to investigate the clinical...

  • Apraxia profile differentiates behavioural variant frontotemporal from Alzheimer's dementia in mild disease stages. Johnen, Andreas; Tokaj, Amelie; Kirschner, Anne; Wiend, Heinz; Lueg, Gero; Duning, Thomas; Lohmann, Hubertus // Journal of Neurology, Neurosurgery & Psychiatry;Jul2015, Vol. 86 Issue 7, p809 

    Objective: Despite refined criteria for behavioural variant frontotemporal dementia (bvFTD), its differentiation from Alzheimer's dementia (AD) remains difficult at early clinical presentation. Apraxia is not considered as a supportive feature for the diagnosis of bvFTD, but for AD. However,...

  • Supranuclear palsy. Thakkar, Raj // GP: General Practitioner;1/7/2013, p34 

    The article presents author's comments on the rare neurodegenerative conditions in Great Britain. It offers information on progressive supranuclear palsy (PSP) or steele-richardson-olszewskisyndrome which is a neurodegenerative condition. It mentions that PSP is misdiagnosed as Alzheimer's...

  • Therapeutic and diagnostic challenges for frontotemporal dementia. D'Alton, Simon; Lewis, Jada // Frontiers in Aging Neuroscience;Jul2014, Vol. 6, preceding p1 

    In the search for therapeutic modifiers, frontotemporal dementia (FTD) has traditionally been overshadowed by other conditions such as Alzheimer's disease. A clinically and pathologically diverse condition, FTD has been galvanized by a number of recent discoveries such as novel genetic variants...

  • Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non Alzheimer's disease tauopathies. Fodero-Tavoletti, Michelle T.; Shozo Furumoto; Taylor, Leanne; McLean, Catriona A.; Mulligan, Rachel S.; Birchall, Ian; Ryuichi Harada; Masters, Colin L.; Kazuhiko Yanai; Yukitsuka Kudo; Rowe, Christopher C.; Nobuyuki Okamura; Villemagne, Victor L. // Alzheimer's Research & Therapy;2014, Vol. 6 Issue 1, p1 

    Introduction The introduction of tau imaging agents such as 18F-THK523, offers new hope for the in vivo assessment of tau deposition in tauopathies such as Alzheimer's disease (AD), where preliminary 18F-THK523-PET studies demonstrated significantly higher cortical retention of 18F-THK523 in AD...

  • Relevance of Mutations in Tau for Understanding the Tauopathies. Goedert, Michel // Current Medicinal Chemistry - Immunology, Endocrine & Metabolic ;Dec2003, Vol. 3 Issue 4, p341 

    Tau protein is the major component of the intracellular filamentous deposits that define a number of neurodegenerative diseases. They include the largely sporadic Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration, Pick's disease and argyrophilic grain disease, as...

  • Neuro-Ophthalmologic Abnormalities in Alzheimer Disease, Parkinson Disease, and Progressive Supranuclear Palsy. Chung, Sophia M. // American Orthoptic Journal;2005, Vol. 55, p39 

    Introduction and Purpose: The visual symptoms of neurodegenerative diseases, specifically Alzheimer disease, Parkinson disease, the two most common neurodegenerative diseases, and progressive supranuclear palsy, may be the initial manifestation of a progressive and emotionally and physically...

  • Visual complaints seen with neurodegenerative diseases. Chung, Sophia M. // Ophthalmology Times;8/15/2005, Vol. 30 Issue 16, p52 

    Reports on the association of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and progressive supranuclear palsy, with various eye movement disorders. Chief visual complaints of patients suffering from neurodegenerative diseases; Characteristics of the Balint's-like...

  • Ocular motor abnormalities in neurodegenerative disorders. Antoniades, C A; Kennard, C // Eye;Feb2015, Vol. 29 Issue 2, p200 

    Eye movements are a source of valuable information to both clinicians and scientists as abnormalities of them frequently act as clues to the localization of a disease process. Classically, they are divided into two main types: those that hold the gaze, keeping images steady on the retina...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics